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We have previously shown that a number of naturally occurring phytoestrogens and derivatives
were effective to induce some measures of neuroprotective responses but at a much lower mag-
nitude than those induced by the female gonadal estrogen 17-estradiol. In the present study, we
sought to investigate whether a combination of select phytoestrogens could enhance neural re-
sponses without affecting the reproductive system. We performed a range of comparative analyses
of the estrogen receptor (ER) / binding profile, and in vitro to in vivo estrogenic activities in
neural and uterine tissues induced by clinically relevant phytoestrogens: genistein, daidzein, equol,
and IBSO03569, when used alone or in combination. Our analyses revealed that both the ER/
binding profile and neural activities associated with individual phytoestrogens are modifiable
when used in combination. Specifically, the combination of genistein plus daidzein plus equol
resulted in the greatest binding selectivity for ER and an overall improved efficacy/safety profile
when compared with single or other combined formulations, including: 1) an approximate 30%
increase in ER-binding selectivity (83-fold over ER); 2) a greater effect on neuronal survival
against toxic insults in primary neurons; 3) an enhanced activity in promoting neural proactive
defense mechanisms against neurodegeneration, including mitochondrial function and -amyloid
degradation; and 4) no effect on uterine growth. These observations suggest that select phytoestro-
gens in combination have the therapeutic potential of an alternative approach to conventional es-
trogen therapy for long-term safe use to reduce the increased risk of cognitive decline and neurode-
generative disease associated with menopause in women. (Endocrinology 150: 770–783, 2009)
Findings of the Women’s Health Initiative (1, 2) and the Wom-en’s Health Initiative Memory Study (3–6), that the overall
risks outweigh the benefits associated with estrogen-containing
hormone therapy (HT), raised serious concerns regarding the use
of HT in women. A consensus has been reached that, among
many factors, “timing” could be a significant regulator of the
health impact of HT on postmenopausal women. HT was found
to be beneficial in reducing the incidence of cardiac disease in
women who initiated the therapy within 10 yr from the onset of
menopause, however, it was detrimental when started at an ad-
vanced age (7, 8). Similarly, HT appears to have a “healthy cell
bias” for neural action (9, 10), suggesting its potential as a pre-
ventive rather than treatment strategy for cognitive decline and
neurodegenerative disease, such as Alzheimer’s (AD), in post-
menopausal women (11, 12). Despite the health benefits asso-
ciated with the timely use of HT, long-term administration of HT
has been associated with an increased risk of breast cancer (13).
In addition, stroke remains a serious risk, regardless of time from
the onset of menopause, for women receiving either estrogen-alone
or combined therapy (8, 14, 15). In recent years, substantial re-
search has focused on the development of alternative approaches
that can mimic estrogenic beneficial impact on women’s health
while not eliciting the adverse effects seen with HT (16).
Plant-derived phytoestrogens, a weaker form than mamma-
lian estrogens, produce estrogenic/antiestrogenic effects depend-
ing on the status of endogenous estrogens and the distribution of
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two subtypes of estrogen receptor (ER), ER and ER, in specific
tissues (17). It is suggested that the low incidence of a number of
sex hormone-related disorders, such as menopausal hot flashes
(18) and breast cancer (19, 20) in Asian women and prostate
cancer in Asian men (21), compared with the incidence in West-
erners, is in part attributable to the higher intake of phytoestro-
gen-rich soy foods in Asians (22, 23). The high intake of soy-
derived phytoestrogens has also been linked to the low
prevalence rate of AD in Asia compared with the Western world
(17). However, this association lacks confirmation from ran-
domized and controlled human studies, which have been found
to be inconsistent. The disparity in outcomes across studies could
be caused by variations in the constitutive composition of phar-
macological preparations of soy extracts (17).
Basic science research determining the impact of phytoestro-
gens on brain functions has been based primarily upon exposure
to either single phytoestrogens or soy diets containing the natural
forms of soy intake seen in Asians. We have previously observed
that a number of clinically relevant phytoestrogens, when used
alone, only generated a small magnitude of neuroprotective re-
sponse when compared with neurons exposed to the endogenous
estrogen 17-estradiol (17-E2), which could be directly related
to their weak binding to ERs (24). In the present study, we sought
to test the hypothesis that the limited activity in the neural system
associated with individual phytoestrogens could be modified
when used in combination. In particular, combined use of ra-
tionally selected phytoestrogens that bind preferentially to ER
over ER could enhance neural responses without affecting the
reproductive system. The strategy to selectively target ER is
built upon recent advancements in understanding the roles of
ER and ER in conveying estrogen actions in the brain and
periphery. First, ER is indicated to play a crucial role in medi-
ating estrogenic activities to sustain neural defense against neu-
rodegeneration (25, 26) and promotion of neural synaptic plas-
ticity, learning, and memory function (27–29). In addition to its
cognitive role, ER has also been suggested as a novel therapeutic
target for the development of therapies for a range of patholog-
ical conditions mediated by ER, including menopausal vaso-
motor symptoms (30) and other brain disorders such as anxiety
(31) and depressive behavior (32). Second, in view of the possi-
bility that simultaneous activation of both ER and ER by their
cognate agonists may diminish their overall efficacy (26), a com-
bined formulation composed solely of ER agonists could reduce
the antagonistic interactions among ER and ER-selective con-
stituents in a random mixture. Third, selective activation of ER
avoids ER-mediated sexual modulation and proliferative re-
sponses known to cause elevated risk for reproductive cancers
associated with the use of the conventional HT in women (33).
Materials and Methods
Chemicals
17-E2 was purchased from Steraloids (Newport, RI). Genistein (G),
daidzein (D), and equol (E) were purchased from Indofine Chemical
(Hillsborough, NJ). IBSO03569 (I) was purchased from InterBioScreen
(Moscow, Russia). The sources of other materials are indicated in the
experimental methods described below.
ER/ competitive binding
The ER/ binding profile of the test compounds or combinations
was determined with a fluorescent polarization competitive binding as-
say (Invitrogen Corp., Carlsbad, CA), as previously described (34). Test
compounds or combinations (composed of equivalent molar of individ-
ual phytoestrogens included) were serially diluted to a 2 concentration
in assay buffer (20 M to 200 pM). A total of 40 l assay buffer mixed
with 2 test compounds or combinations was added to a 384-well non-
binding surface microplate, followed by addition of 40 l preincubated
2 complex of ER (30 nM) or ER (60 nM) and a fluorescent estrogen
ligand EL Red (2 nM) for a final volume of 80 l. After a 6-h incubation,
the polarization values were measured using a GENios Pro microplate
reader (Tecan, San Jose, CA) at excitation/emission 535/590 nm and
plotted against the logarithm of the concentrations of the test compounds
or combinations. IC50 values were determined from the plot by a non-
linear least-squares analysis using GraphPad Prism version 4.03 (Graph-
Pad Software Inc., San Diego, CA).
Animals
The use of animals was approved by the Institutional Animal Care
and Use Committee at the University of Southern California (Protocol
No. 10780). Embryonic d 18 fetuses derived from time-pregnant Sprague
Dawley rats (Harlan, Indianapolis, IN) were used to obtain primary
neuronal cultures for in vitro experiments. Ovariectomized young adult
female Sprague Dawley rats (14–16 wk old, weighing 270–290 g; Har-
lan) were used for in vivo experiments. Animals were housed under
controlled conditions of temperature (22 C), humidity, and light (14 h
light, 10 h dark) with water and food available ad libitum.
Primary neuronal culture
Hippocampal neuronal cultures were prepared as previously de-
scribed (26). Briefly, hippocampi derived from embryonic d 18 rat fetuses
were treated with 0.02% trypsin in Hanks’ balanced salt solution (137
mM NaCl, 5.4 mM KCl, 0.4 mM KH2PO4, 0.34 mM Na2HPO4  7H2O,
10.0 mM glucose, and 10.0 mM HEPES) at 37 C for 5 min and dissociated
by passage through fire-polished constricted Pasteur pipettes. Neurons
were grown in Neurobasal medium (NBM) (Invitrogen) supplemented
with B27, 5 U/ml penicillin, 5 g/ml streptomycin, 0.5 mM glutamine,
and 25 M glutamate at 37 C in humidified 5% CO2 atmosphere for the
first 3 d and NBM without glutamate afterwards.
Glutamate exposure and neuronal viability
Hippocampal neuronal cultures grown on 96-well culture plates for
7 d in vitro were pretreated with vehicle alone, test compounds, or com-
binations for 48 h, followed by exposure to 200 M glutamate for 5 min
in HEPES-buffered saline solution containing: 100 mM NaCl, 2.0 mM
KCl, 2.5 mM CaCl2, 1.0 mM MgSO4, 1.0 mM NaH2PO4, 4.2 mM
NaHCO3, 10.0 mM glucose, and 12.5 mM HEPES. After glutamate ex-
posure, cultures were washed with HEPES-buffered saline solution and
replaced with fresh NBM containing the test compounds or combina-
tions. Cultures were returned to the culture incubator and allowed to
incubate for an additional 24 h before neuronal viability analyses by a
colorimetric measurement of lactate dehydrogenase (LDH) release in the
media and/or a fluorometric measurement of live-cell calcein acetoxym-
ethyl ester staining as previously described (26), on the following day.
A1–42 exposure and neuronal viability
Fibrillar A1–42 (American Peptide, Sunnyvale, CA) was prepared as
previously described (35). Hippocampal neuronal cultures grown on
96-well culture plates for 7 d in vitro were pretreated with vehicle alone,
test compounds, or combinations for 48 h, followed by exposure to
freshly prepared 3 M A1–42 in NBM in the presence of vehicle alone,
test compounds, or combinations at 37 C for 3 d before neuronal viability
analyses using a multiplex cytotoxicity assay (Promega Corp., Madison,
WI), which contains two fluorogenic peptide substrates allowing a si-
multaneous measurement of live and dead-cell protease activities. GF-
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AFC is a cell-permeant live-cell protease substrate and cleaved to gen-
erate a fluorescent signal proportional to the number of live cells in the
cultures. Bis-AAF-R110 is a cell-impermeant dead-cell protease sub-
strate and released from cells that have lost membrane integrity, there-
fore, it serves as a marker of cytotoxicity. Briefly, after A1–42 exposure,
80 l culture medium was kept in each well of the culture plate, and 80
l of the assay buffer mixed with two substrates was added to incubate
at 37 C for 45–60 min. The fluorescence intensities were measured on a
SpectraMax dual-wavelength-scanning microplate spectrofluorometer
(Molecular Devices, Sunnyvale, CA) at excitation/emission filter com-
binations, 400/505 nm for live-cell fluorescence and 485/520 nm for
dead-cell fluorescence.
Animal treatment, tissue collection, and uterine weight
Ovariectomized young adult female rats were placed on a phytoestro-
gen-reduced diet, TD.96155 (Harlan Teklad, Madison, WI) during a
2-wk recovery from the surgery before the treatment. Test compounds or
combinations (composed of equivalent weight of individual phytoestro-
gens included) were first dissolved in analytically pure dimethylsulfoxide
and then diluted in corn oil (50 l dimethylsulfoxide in 950 l corn oil)
to the working concentrations at 100 g/ml for 17-E2 and 10 mg/ml for
phytoestrogens. Rats were treated once daily for 2 d with a sc injection
of vehicle alone, 17-E2 70 g/kg body weight (BW), G (6 mg/kg BW),
or phytoestrogen combinations (6 mg/kg BW). After the second injec-
tion, rats fasted for 24 h before being killed and brain dissection. Hip-
pocampal and cortical tissues were collected from one hemisphere. The
remaining brain tissues minus cerebellum, pineal gland, and brainstem
were used for mitochondrial isolations. Uteri were excised, trimmed of
fat and connective tissue, and a wet weight was recorded. The uteri were
then air-dried for 1 wk and then at 70 C overnight, and the dry weight
was recorded.
Forebrain mitochondrial isolation
Rat forebrain tissues were homogenized in mitochondrial isolation
buffer (MIB) containing 320 mM sucrose, 10 mM Tris-HCl, and 1 mM
EDTA (pH 7.4)-KOH, with freshly added 0.5 mg/ml-MIB of BSA and 10
l/ml-MIB of protease inhibitor cocktail right before use, at 4 C. Ho-
mogenates were centrifuged at 1330  g for 5 min. Pellets were re-
homogenized and centrifuged. The two postnuclear supernatants were
combined and centrifuged at 21,200  g for 10 min. The resulting crude
mitochondrial pellets were resuspended in 15% Percoll (Sigma, St. Louis,
MO) and layered over a 23%/40% discontinuous Percoll gradient, and
centrifuged at 31,000  g for 10 min. The fraction accumulating at the
23%/40% interface was collected and washed with 10 ml MIB by cen-
trifugation at 16,700  g for 13 min. The pellets were then transferred
to 1.5-ml Eppendorf tubes (VWR, Brisbane, CA) and centrifuged at 6600 
g for 8 min. The purified mitochondrial pellets were resuspended in MIB to
an approximate concentration of 5 mg/ml. The purity and integrity of iso-
lated mitochondria were confirmed as previously described (36). The iso-
lated mitochondrial samples were used immediately for respiratory activity
measurements or stored at 70 C for enzymatic assays.
Mitochondrial respiratory activity
Mitochondrial respiratory activity was measured polygraphically us-
ing a Clarke-type oxygen electrode (Hansatech Instruments Ltd., Nor-
folk, UK) at 37 C. A total of 100 g isolated mitochondria was added in
a magnetically stirred chamber filled with 500 l respiration buffer 25
mM sucrose, 75 mM mannitol, 5 mM KH2PO4, 100 mM KCl, 0.05 mM
EDTA, 20 mM HEPES, and 5 mM MgCl2 (pH 7.4)-KOH. After a basal
respiration recording, mitochondrial state 4 respiration was measured
after the addition of 10.5 l substrates, malate (2.5 mM)/glutamate (2.5
mM). State 3 respiration was measured after the addition of 2.5 l ADP
(350 M). Respiratory control ratio (RCR) was calculated as the ratio
between the rate of oxygen uptake at state 3 and the rate of oxygen
uptake at state 4.
Mitochondrial cytochrome c oxidase (COX) activity
Mitochondrial COX activity was measured using a microplate im-
munocapture method (MS427) developed by MitoSciences (Eugene,
OR), which spectrophotometrically monitors the change in absorbance
at 550 nm after the oxidation of reduced cytochrome c. Briefly, COX in
25 g isolated mitochondria was first immunocaptured onto the assay
plate, followed by the addition of the substrate, reduced cytochrome c.
Colorimetric absorbance was measured at 550 nm at 30 C, and recorded
every 5 min for 115 min, on a Benchmark Plus spectrophotometer
equipped with a Microplate Manager version 5.2 Build 103 software
(Bio-Rad Laboratories, Inc., Hercules, CA). Because the reaction is prod-
uct inhibited, COX activity was expressed as the initial rate of oxidation
of reduced cytochrome c, and determined by calculating the initial slope
between two time points within the linear region (5–15 min).
Western blot
Protein extraction and concentration determination were performed
as previously described (26). A total 20–40 g protein samples was
loaded per lane and separated by electrophoresis on 10–12% SDS-
PAGE. Proteins were then electrotransferred to polyvinylidene fluoride
membranes, which were probed with primary antibodies against Bcl-2
(1:250; Zymed Laboratories, Inc., San Francisco, CA), Bcl-xL (1:500;
Zymed Laboratories), or insulin-degrading enzyme (IDE) (1:1000; Cal-
biochem, San Diego, CA), at 4 C overnight and then with horseradish
peroxidase-conjugated secondary antibodies (Vector Laboratories, Bur-
lingame, CA). -Tubulin (Abcam, Inc., Cambridge, MA) was used as the
loading control. Bands were visualized with a 3,3,5,5-tetramethylben-
zidine peroxidase kit (Vector Laboratories) or by chemiluminescence
using an enhanced chemiluminescence detection kit (Amersham Bio-
sciences Inc., Piscataway, NJ). Relative intensities of the immunoreactive
bands were quantified by an OD analysis using Un-Scan-It version 5.1
(Silk Scientific, Orem, UT).
Statistical analyses
Data are presented as group means  SEM. Statistically significant
differences were determined by a one-way ANOVA followed by a Stu-
dent-Newman-Keuls post hoc analysis.
Results
ER/ binding profile
A fluorescence polarization-based competitive binding assay,
which has been validated in our previous analyses (34, 37), was
first conducted to determine the ER/ binding profile of test
phytoestrogens when used alone or in combination (Fig. 1). Fig-
ure 2 illustrates the binding curves, and data derived from the
binding curves are summarized in Table 1. The binding IC50 of
17-E2, 25.3 nM for ER (R2  0.98), and 32.5 nM for ER
(R2  0.96) were consistent with the values reported previously
(34, 37). As expected the negative control compound, proges-
terone, did not bind to either ER subtypes. Among individual
phytoestrogens, G exhibited the maximal binding to both ER
(IC50  4.74 M; R
2  0.98) and ER (IC50  78.9 nM; R
2 
0.99), with an approximate 60-fold preference for ER over
ER. The binding IC50 of G to ER was approximately 41% of
the value from 17-E2. In comparison with G, the binding af-
finities of D to both ER (IC50  26.7 M; R
2  0.79) and ER
(IC50  1.74 M; R
2  0.99) were weaker but maintained an
approximate 14-fold binding preference for ER. E exhibited a
similar binding affinity to G for ER (IC50  5.88 M; R
2 
0.99), but with a less, approximately 10-fold, binding preference
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to ER (IC50  0.58 M; R
2  1.00). Although I exhibited the
greatest binding selectivity toward ER (100-fold), the binding
affinity was the lowest, with an IC50 at 1695 M for ER (R
2 
0.99) and 7.82 M for ER (R2  1.00). The combination of G
and D exhibited a decreased binding affinity compared with G
alone, with IC50 values (IC50  9.90 M for ER; R
2  0.99;
IC50  0.16 M for ER; R
2  1.00) approximately 50% of G
alone. However, the binding selectivity of G plus D was slightly

















































































































































































































FIG. 2. Competition binding curves for ER and ER. Data were generated with a fluorescence polarization-based competitive binding assay using full-length human
ER and ER, and plotted against the logarithm of serially diluted concentrations of the test compounds or combinations. Progesterone served as a negative control.




















FIG. 1. Chemical structures of 17-E2 and phytoestrogens tested in the present study. G and D are active aglycones of glucoside conjugates, genistin and daidzin, two
main isoflavone constituents widely distributed in legumes such as soybeans. E is not of plant origin yet can be produced from D by enteric microfloral metabolism in a
subset of human populations. I is a flavone derivative of D with an additional hydroxyl group attached to the 2-phenol ring.
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higher, with an approximate 63-fold binding preference for ER.
The combination of G, D, and E exhibited a greater decrease in
the binding affinity toward ER (IC50  15.7 M; R
2  0.99)
than the decrease toward ER (IC50  0.19 M; R
2  1.00),
which was slightly lower than the value from G plus D. However,
G plus D plus E exhibited a much improved, approximately
83-fold, binding preference for ER, which represents an ap-
proximate 30% increase compared with G alone or G plus D.
The combination of G, D, E, and I exhibited a similar binding
affinity to G plus D plus E toward ER (IC50  15.9 M; R
2 
0.99) but with a lower, approximately 61-fold, binding prefer-
ence for ER (IC50  0.26 M; R
2  0.99), which is similar to
the selectivity from the combination of G plus D.
Neuroprotective activity in vitro
Neuroprotective effects of test phytoestrogens, when admin-
istered alone or in combination, were evaluated in rat primary
hippocampal neuronal cultures challenged with neurotoxic glu-
tamate or A1–42. A dose-response analysis was first conducted
to determine the concentration for each phytoestrogen resulting
in the maximal neuronal survival after an acute exposure to a
supraphysiological concentration of glutamate. LDH release in
the culture medium served as an indicator of neuronal membrane
integrity, a minimum requirement for neuroprotection (38).
Data summarized in Fig. 3A demonstrated that cultures exposed
to glutamate alone had significantly increased LDH release in the
medium as compared with vehicle-treated control cultures (##,
P 	 0.01), although the relative amount of release varied across
cultures. All four phytoestrogens induced a concentration-de-
pendent and moderate reduction of LDH release as compared
with glutamate alone-treated cultures (*, P 	 005 and **, P 	
0.01). A maximal reduction occurred at 100 nM, exhibiting sig-
nificant differences from neuronal responses induced by some of
the neighboring concentrations (, P 	 0.05 and , P 	 0.01, ,
P 	 0.05 and , P 	 0.01, 
, P 	 0.05, and 

, P 	 0.01,
compared with cultures treated with 10 nM, 1 M, and 10 M
phytoestrogens, respectively).
Further analyses were conducted to determine whether the
test phytoestrogens administered at the concentration (100 nM)
that produced the maximal protection against glutamate-in-
duced damage in neuronal membrane integrity would be effec-
tive in protecting neurons against glutamate-induced deficits in
metabolic activity, and whether combined use of these phy-
toestrogens would increase neuroprotective response when com-
pared with single administrations. Neuronal viability was as-
sessed by the live-cell calcein staining, which served as an
indicator of neuronal metabolic activity (38). Data shown in Fig.
3B demonstrated that a 5-min exposure to 100 nM glutamate was
not only deleterious to neuronal membrane integrity as previ-
ously determined, but also toxic to neuronal metabolic viability,
as indicated by a significant reduction in calcein staining (87.4 
1.4% relative to control cultures) compared with vehicle-treated
control cultures (##, P 	 0.01). Cultures treated with 17-E2 (10
nM) produced an average of 43.0% increase in calcein fluores-
cence (92.8  1.6% relative to control cultures) compared with
glutamate alone-treated cultures (*, P 	 0.05). When used alone,
only G induced a significant increase (36.4%) in calcein fluo-
rescence (92.0  0.9% relative to control cultures) compared
with glutamate alone-treated cultures (*, P 	 0.05). Although
the other three phytoestrogens, D, E and I, when administered at
100 nM, were protective at the level of neuronal membrane in-
tegrity, they were insufficient to induce a statistically significant
effect at the level of neuronal metabolic activity. In comparison,
combined use of select phytoestrogens (with each individual phy-
toestrogen at 100 nM) exerted an increased neuroprotective ef-
ficacy. The combination of G plus D induced an average of
42.5% increase in calcein fluorescence (92.8  2.2% relative to
control cultures), which, however, was not statistically signifi-
cant. The combination of G plus D plus E induced a maximal
effect (95.6  0.7% relative to control cultures) against gluta-






Nonbinding RBA (%)b R2c
IC50 (M)
nonbinding RBA (%) R2
Progesterone
17-E2 0.0253 100.0 0.9791 0.0325 100.0 0.9611 0.78
G 4.735 0.5343 0.9811 0.0789 41.12 0.9908 60.0
D 26.65 0.0949 0.7876 1.738 1.867 0.9883 14.27
E 5.876 0.4306 0.9948 0.5825 5.571 0.9986 10.09
I 1695 0.0015 0.9917 7.819 0.415 0.9959 100
GD 9.896 0.2557 0.9865 0.1574 20.62 0.9970 62.87
GDE 15.71 0.1610 0.9925 0.1902 17.06 0.9969 82.60
GDEI 15.85 0.1596 0.9932 0.2615 12.41 0.9891 60.61
a The concentration of the test compounds or combinations resulting in a half-maximal shift in polarization value was determined from the binding curve (Fig. 2) by a
nonlinear least-squares analysis.
b The relative binding affinity (RBA) of the test compounds or combinations that is expressed as the percentage of the binding affinity of 17-E2 (relative binding
affinity  100%).
c The goodness of fit of nonlinear regression between the binding curve and the data. Ranging between 0.0 and 1.0, higher values indicate that the curve fits the data
better. A fit with a R2 at 1.0 indicates that all points lie exactly on the curve with no scatter.
d Selectivity ( / ) refers to the fold binding selectivity of the test compounds or combinations for ER over ER , which was calculated as the ratio between the
binding IC50 for ER and the IC50 for ER.
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mate insult (64.8  5.6% increase in calcein fluorescence com-
pared with glutamate alone-treated cultures; **, P 	 0.01),
which was significantly greater than the effect induced by
17-E2 (, P 	 0.05). The combination of G plus D plus E plus
I induced an average of 48.5% increase in (93.5  0.9% relative
to control cultures) compared with glutamate alone-treated cul-
tures (*, P 	 0.05).
Based on the significant neuroprotective activity exhibited by
combinations of G plus D plus E and G plus D plus E plus I,
subsequent experimentswere conducted todetermine the impactof
thesecombinedformulationsonneuronalsurvivalwhenchallenged
with an extended exposure to an aggregated form of A1–42. Neu-
ronal viability was assessed by a dual measurement of live-cell
AFC and dead-cell R110 staining, as indicators of neuronal met-
abolic activity and membrane integrity, respectively. Data
shown in Fig. 3C demonstrated that a 2-d exposure to 3.0 M
A1–42 was significantly neurotoxic, as evidenced by both re-
duced live-cell AFC (40.2  2.6% relative to control cultures)
and increased dead-cell R110 staining (1384.9  118.8% rela-
tive to control cultures) compared with vehicle-treated control
cultures (##, P 	 0.01). Treatment with 17-E2 induced an av-
erage of 45.4% increase in AFC (67.3  6.2% relative to control
cultures) and an average of 54.1% reduction in R110 staining
(690.4  60.3% relative to control cultures) compared with
A1–42 alone-treated cultures (**, P 	 0.01). Consistent with the
data against glutamate, the combination of G plus D plus E
exerted the greatest effect on both neuronal metabolic viability
measured by AFC staining (68.6  3.7% relative to control cul-
tures; an average of 47.6% increase compared with A1–42
alone-treated cultures; **, P 	 0.01; , P 	 0.05 compared with
G plus D plus E plus I-treated cultures) and membrane integrity
measured by R110 staining (538.8  71.1% relative to control
cultures; an average of 65.8% reduction compared with A1–42
alone-treated cultures; **, P 	 0.01; , P 	 0.05 compared with
17-E2-treated cultures). The combination of G plus D plus E
plus I induced an average of 32.2% increase in AFC staining
(59.5  1.4% relative to control cultures) and an average of
58.0% reduction in R110 staining (639.6  92.9% relative to
control cultures), both of which were statistically significant rel-
ative to A1–42 alone-treated cultures (**, P 	 0.01).
Regulation of brain mitochondrial bioenergetics in vivo
To determine whether the in vitro findings were predictive of
in vivo efficacy, after experiments conducted in ovariectomized
adult female rats compared in vivo estrogenic responses in neural
and uterine tissues, induced by 17-E2 and three phytoestrogen
formulations: G alone and combinations of G plus D plus E and
G plus D plus E plus I, which were found to be significantly
neuroprotective in vitro. The dosage of 17-E2 (70 g/kg  d)
was designed to be commensurate with a commonly used dose
(0.625 mg/kg  d) reported in epidemiological and clinical studies.
The dosage of phytoestrogen formulations (6 mg/kg  d) was com-
mensuratewith50mg/dexposure inhumansbasedonanestimated
amount of total phytoestrogen intake in Asian populations.
We have previously found that 17-E2 promotes brain mi-
tochondrial proteome involved in oxidative phosphorylation




































































































































































FIG. 3. Neuroprotective activity against glutamate (A and B) and A1–42-
induced toxic insults (C) in rat primary hippocampal neurons. Results are
presented as the percentage of values produced by vehicle-treated control
cultures. A “break” in y-axis (B and C) was used to demonstrate the differences
among treatment groups. ##, P 	 0.01 compared with vehicle-treated control
cultures; *, P 	 0.05 and **, P 	 0.01 compared with glutamate or A1–42
alone-treated cultures. In A, , P 	 0.05 and , P 	 0.01 between 10 and 100
nM; , P 	 0.05 and , P 	 0.01 between 100 nM and 1 M; 	, P 	 0.05 and 		,
P 	 0.01 between 100 nM and 10 M. In B and C, , P 	 0.05 between 17-E2
and G  D  E-treated cultures; , P 	 0.05 between G  D  E and G-treated
cultures; , P 	 0.05 between G  D  E and G  D  E  I-treated cultures.
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drial functional decline that has been implicated in a variety of
neurodegenerative diseases, including AD and Parkinson’s (39–
42). In this experiment, rat forebrain mitochondria were ana-
lyzed to determine whether phytoestrogen formulations would
have a similar impact on mitoenergetics as determined by respi-
ratory efficiency as a primary and COX enzymatic activity as a
secondary indicator. As shown in Fig. 4, consistent with our
previous report (36), rats treated with 17-E2 ((70 g/kg  d for
2 d) exhibited a significantly enhanced mitochondrial oxygen
consumption with an average increase of 42.7% (7.9%) in
RCR (RCR  3.96  0.22) compared with vehicle alone-treated
control rats (RCR  2.78  0.09; **, P 	 0.01). Oxygen con-
sumption in rats exposed to G alone (6 mg/kg  d for 2 d) did not
exhibit a significant change (RCR  2.96  0.17) as compared
with control rats. In contrast, RCR in rats exposed to the com-
bination of G plus D plus E (6 mg/kg  d for 2 d; RCR  3.67 
0.04) was significantly enhanced with an average increase of
32.2% (1.5%) as compared with control rats (**, P 	 0.01).
Similarly, exposure to the combination of G plus D plus E plus
I (6 mg/kg  d for 2 d; RCR  3.64  0.32) induced an average
increase of 31.2% (11.5%) compared with control rats (*, P 	
0.05). Among four treatment groups, there was a statistically
significant difference between 17-E2 and G (, P 	 0.05) as well
as between G plus D plus E and G treatment groups (, P 	 0.05).
The variance within the G plus D plus E plus I-treated group
prohibited a significant difference from G alone-treated group.
A similar trend was observed for the enzymatic activity of
COX as shown in Fig. 5. Consistent with our previous report
(36), 17-E2 treatment induced a significant increase (73.3 
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FIG. 4. Regulation of forebrain mitochondrial respiratory activity in ovariectomized adult female rats. A, Time-lapse oxygen uptake. B, Percent (%) increase in
mitochondrial respiratory activity compared with vehicle-treated control rats (n 
 4). *, P 	 0.05 and **, P 	 0.01; , P 	 0.05 compared with G-treated rats.
Mal/Glut, Malate/glutamate; Mito, mitochondria.
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alone-treated control rats (**, P 	 0.01). In contrast to the lack
of an effect on mitochondrial respiration, rats treated with G
alone exhibited a moderate but statistically significant enhance-
ment in COX activity (21.3  0.8% increase relative to control
rats; *, P 	 0.05). Similar to the data on respiration, rats treated
with the combination of G plus D plus E or G plus D plus E plus
I induced an average increase of 62.7% (10.8% **, P 	 0.01)
and 48.0% (16.2%; *, P 	 0.01), respectively, in COX activity
as compared with control rats. Among the four treatment
groups, a statistically significant difference occurred between
17-E2 and G (, P 	 0.05), as well as between G plus D plus E
and G treatment groups (, P 	 0.05). Consistent with the re-
spiratory activity, there was no significant difference between G
plus D plus E plus I and G treatment groups.
Regulation of brain mitochondrial antiapoptotic
proteins in vivo
In association with impact on mitochondrial bioenergetic ef-
ficiency, up-regulation of brain mitochondrial antiapoptotic
proteins Bcl-2 and Bcl-xL has also been indicated as part of neu-
roprotective mechanisms induced by 17-E2 (43, 44). In this
experiment, Western blot analyses of hippocampal protein sam-
ples prepared from the opposite hemispheres of treated rats were

















































































































FIG. 5. Regulation of forebrain mitochondrial COX activity in ovariectomized adult female rats. A, Time-lapse change in absorbance (first 20 min). B, Percent (%)
increase in mitochondrial COX activity compared with vehicle-treated control rats (n 
 4). *, P 	 0.05 and **, P 	 0.01; , P 	 0.05 compared with G-treated rats.
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FIG. 6. Regulation of mitochondrial antiapoptotic proteins, Bcl-2/Bcl-xL (A), and A-degrading enzymes, IDE/NEP (B), expression in hippocampal tissues derived from
ovariectomized adult female rats. Results are presented as the percent (%) increase compared with vehicle-treated control rats (n 
 4). *, P 	 0.05 and **, P 	 0.01;
, P 	 0.05 and , P 	 0.01 compared with 17-E2-treated rats; , P 	 0.01 compared with G-treated rats; , P 	 0.01 compared with G  D  E  I-treated rats.
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nations would regulate the expression of Bcl-2 and Bcl-xL, and
if so, whether such a regulation correlated with their regulation
of brain mitochondrial bioenergetic efficiency. Consistent with
our previous reports (45, 46) and the present data for RCR and
COX activity, treatment with 17-E2 (70 g/kg  d for 2 d) in-
duced a significant increase in both Bcl-2 (64.8  4.0% increase
compared with vehicle alone-treated control rats; **, P 	 0.01)
and Bcl-xL expression (55.2  11.2% increase compared with
control rats; *, P 	 0.05) in rat hippocampal tissues (Fig. 6A). In
contrast to respiratory and COX activities, which were markedly
lower in rats treated with G alone than the other three treatment
groups, G alone (6 mg/kg  d for 2 d) induced a magnitude of
increase comparable to 17-E2-treated rats in both Bcl-2, with
an average increase of 51.9% (6.2%; **, P 	 0.01), and Bcl-xL
expression, with an average increase of 67.8% (0.7%; **, P 	
0.01), compared with control rats (Fig. 6A). Increase in Bcl-2
expression (43.2  4.1% increase compared with control rats; *,
P 	 0.05) induced by the combination of G plus D plus E (6
mg/kg  d for 2 d) was significantly lower than that induced by
17-E2 (, P 	 0.01). There was a greater variance in Bcl-xL
expression in G plus D plus E-treated rats, with an average in-
crease of 58.9% (11.7%) compared with control rats (*, P 	
0.05). Rats treated with G plus D plus E plus I (6 mg/kg  d for
2 d) did not exhibit a significant change in either protein, al-
though there was an average increase of 38.6% (11.7%) in
Bcl-xL expression, which, however, was not statistically signif-
icant due to the large variance among animals. Bcl-2 expression
(1.5  4.0% increase compared with control rats) induced by G
plus D plus E plus I was significantly lower than all other treat-
ment groups (, P 	 0.01).
Regulation of brain A-degrading enzymes in vivo
A major neuropathological hallmark of AD is the significant
deposition of A peptide, which can lead to formation of A
plaques. Clinical investigations have revealed a strong link be-
tween a deficit in expression and activity of A-degrading en-
zymes and AD pathogenesis (47, 48). Several A-degrading en-
zymes have been identified, including IDE and neprilysin (NEP),
which appear to play a more significant role than others in reg-
ulating A catabolic clearance in the brain. In this experiment,
Western blot analyses of the same hippocampal protein samples
used in Bcl-2/Bcl-xL analyses were conducted to determine
whether the test compounds or combinations would potentially
impact brain A metabolism via regulation of the expression of
A-degrading enzymes such as IDE and NEP. Results shown in
Fig. 6 demonstrated that all treatment groups exhibited an en-
hanced expression of both IDE and NEP (Fig. 6B). Specifically,
rats treated with 17-E2 (70 g/kg  d for 2 d) exhibited an av-
erage increase of 42.4% (3.9%) in IDE and a 44.0% (1.8%)
increase in NEP expression, both of which were statistically sig-
nificant compared with vehicle alone-treated control rats (**,
P 	 0.01). Among three groups treated with different phy-
toestrogen formulations, the combination of G plus D plus E (6
mg/kg  d for 2 d) induced a magnitude of up-regulation of IDE
similar to 17-E2 (44.1  7.2% increase compared with control
rats; **, P 	 0.01). In comparison, G alone (6 mg/kg  d for 2 d)
induced an average increase of 21.6% (3.9%) compared with
vehicle-treated control rats, which was not statistically signifi-
cant (, P 	 0.05 compared with 17-E2-treated rats). The com-
bination of G plus D plus E plus I (6 mg/kg  d for 2 d) induced
a slightly smaller magnitude of change in IDE expression (35.6 
8.4% increase compared with control rats; *, P 	 0.05) than that
induced by G plus D plus E. For induction of NEP expression, the
combination of G plus D plus E induced a maximal effect among
all treatment groups, with an average increase of 73.8%
(3.4%) (**, P 	 0.01 compared with control rats), which was
statistically greater than that induced by either 17-E2 (, P 	
0.01) or G alone (, P 	 0.01). Although G alone induced a
significant increase in NEP expression (31.2  1.2% increase
compared with control rats; **, P 	 0.01), the magnitude of
induction was lower than that induced by G plus D plus E or
17-E2 (, P 	 0.01). Rats treated with G plus D plus E plus I
had a greater variance and exhibited an average increase of
40.4% (14.4%) in NEP expression relative to control rats
(*, P 	 0.05).
Impact on uterine growth in vivo
Induction of proliferative responses and risk of cancers in
reproductive tissues has been a major concern to women who
receive the current form of estrogen-containing HT (17). In this
experiment, both the wet and dry weights of uteri excised from
treated rats at the time of being killed were recorded as an indi-
cator of estrogenic activity on uterine growth. Data shown in
Table 2 revealed that as expected, treatment with 17-E2 (70
g/kg  d for 2 d) induced a marked increase in both wet (120.2 
25.1% increase compared with vehicle alone-treated control
rats; **, P 	 0.01) and dry uterine weight (76.7  15.6% in-
crease compared with control rats; **, P 	 0.01). Treatment
TABLE 2. Effect on uterine weight in ovariectomized adult female rats
Treatment
Uterine weight
Wet weight (mg) Increase (%)a Dry weight (mg) Increase (%)
Control (vehicle) 127.62  10.75 0.00  8.42 26.42  2.45 0.00  9.27
17-E2 (70 g/kg BW) 281.06  32.00b 120.23  25.07b 46.70  4.13b 76.74  15.63b
G (6 mg/kg BW) 144.11  10.18 12.92  7.97 28.14  2.04 6.49  7.71
GDE (6 mg/kg BW) 119.84  1.19 6.10  0.93 23.71  0.04 10.26  0.13
GDEI (6 mg/kg BW) 146.99  18.45 15.17  14.46 28.73  3.67 8.73  13.90
a Increase (%) in uterine weight compared with vehicle-treated control rats and expressed as the percentage of control (set as zero).
b P 	 0.01 compared with any other treatment groups.
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with G alone (6 mg/kg  d for 2 d, 12.9  8.0% and 6.5  7.7%
increase in wet and dry weight, respectively, compared with con-
trol rats), the combination of G plus D plus E (6 mg/kg  d for 2 d,
6.1  0.9% and 10.3  0.1% increase in wet and dry weight,
respectively, compared with control rats), or G plus D plus E plus
I (6 mg/kg  d for 2 d, 15.2  14.5% and 8.7  13.9% increase
in wet and dry weight, respectively, compared with control rats)
did not produce a significant impact on uterine weight. Although
there was not a statistical significance, a trend toward a slightly
declined uterine weight was observed in rats treated with the
combination of G plus D plus E, but not in those treated with
either G alone or the combination of G plus D plus E plus I,
compared with vehicle-treated control rats.
Discussion
In the present study, we conducted a range of comparative anal-
yses of: 1) the ER/ binding profile; 2) in vitro to in vivo neural
responses, including neuronal survival against glutamate and
A1–42-induced toxic insults in rat primary hippocampal neu-
rons, regulation of rat forebrain mitochondrial bioenergetic ac-
tivity, and hippocampal expression of antiapoptotic and A-
degrading proteins; and 3) the impact on uterine growth induced
by four clinically relevant phytoestrogens when used alone or in
combination.
One major finding of these analyses is that the ER/ binding
profile associated with individual phytoestrogens can be modi-
fied when they are used in combination. Figure 2 and Table 1
reveal that, of four test phytoestrogens, G exhibited the maximal
binding affinity for both ERs, particularly for ER (41% of
17-E2), followed by E (14% of G), D (34% of E), and then
I (22% of D), despite their binding selectivity for ER with the
following disparate order: I (100-fold) G (60-fold) D
(14-fold) E (10-fold). These profiles were altered when
these phytoestrogens were used in combination. The combina-
tion of G with D (G plus D), or D and E (G plus D plus E), or D,
E, and I (G plus D plus E plus I) yielded a 50% or greater decrease
in the ER-binding affinity, at approximately 50, 41, and 30%
of G for G plus D, G plus D plus E, and G plus D plus E plus I,
respectively. Nevertheless, the ER-binding selectivity of these
combinations remained the same or increased compared with G
alone. Combinations of G plus D and G plus D plus E plus I
exhibited a similar selectivity for ER to G, at approximately 63-
and 61-fold, respectively. In comparison, G plus D plus E ex-
hibited an approximate 30% increase (83-fold) compared with
G. These results indicate that the addition of a weak ER ligand
in a formulation could induce a competitive binding and lead to
a decrease in the overall binding affinity. However, such a re-
duction in the binding affinity could be offset by a substantial
increase in the binding selectivity for ER.
Another major finding is that a select combination of phy-
toestrogens can produce increased estrogenic activities in the
neural system compared with administration of single phy-
toestrogens. Such an increase was first demonstrated in in vitro
analyses of neuroprotective responses in rat primary hippocam-
pal neurons. We observed that despite the fact that individual
phytoestrogens were effective in promoting neuronal membrane
integrity against glutamate-induced insult, only G was sufficient
in exerting significant protection on neuronal metabolic viability
against the insult. Of three combinations on the same measure of
neuronal metabolic activity, no effect was evident from G plus D.
In comparison, G plus D plus E not only induced a significant
increase in neuronal metabolic viability against the insult from
glutamate when compared with neuronal response to G alone, it
was also highly protective of both neuronal membrane integrity
and metabolic viability against the insult induced by A1–42.
Neurons treated with G plus D plus E plus I also exhibited en-
hanced survival against both glutamate and A1–42, however,
the overall magnitude was lower than responses in neurons
treated with G plus D plus E. In particular, after A1–42 expo-
sure, metabolically live neurons were significantly less evident in
cultures treated with G plus D plus E plus I than those treated
with G plus D plus E.
An increase in neural responses induced by a select combi-
nation of test phytoestrogens was also evident in vivo. Adult
female rats treated with the combination of G plus D plus E, at
a clinically relevant dosage, exhibited a significant increase in
forebrain mitochondrial bioenergetic function, including respi-
ratory efficiency and COX enzymatic activity. In comparison,
rats treated with G alone at the same dosage did not show a
significant change in respiration, although there was an increase
in COX enzymatic activity but at a much lower magnitude rel-
ative to G plus D plus E-treated rats. On both measurements, the
effects induced by G plus D plus E were significantly greater than
those from G alone. Consistent with in vitro neuroprotection, the
magnitude of change induced by G plus D plus E plus I was lower
than that induced by G plus D plus E, although there was no
significant difference between the two combinations. The en-
hanced mitoenergetic efficiency was to some extent paralleled by
an increase in the expression of the mitochondrial antiapoptotic
proteins Bcl-2/Bcl-xL. Although G was ineffective at enhancing
mitoenergetic function, it exerted a significant impact on the
expression of Bcl-2/Bcl-xL, with an efficacy on par with that of
G plus D plus E. However, the effect produced by G plus D plus
E was negated by the presence of I. These results may suggest a
dissociation between regulation of antiapoptotic proteins and
activation of signaling cascades that mediate mitochondrial
function. It appears that induction of Bcl-2/Bcl-xL more closely
correlates with the ER-binding affinity, which, however, was
not the main determinant of brain mitoenergetic function. More-
over, combinations of G plus D plus E and G plus D plus E plus
I exerted a marked effect on the expression of the A-degrading
enzymes IDE and NEP. It was particularly notable that G plus D
plus E induced an increase in NEP expression significantly
greater than that induced by 17-E2. For G alone, there was no
change in the expression of IDE, although there was a significant
increase in the expression of NEP, but at a much lower magni-
tude than that induced by either 17-E2 or G plus D plus E.
Consistent with most of the observations presented in this study,
G plus D plus E was more efficacious than G plus D plus E plus I.
These observations indicate that the overall neural activities
associated with a phytoestrogen combination are not a simple
sum of individual effects but, rather, the net result of comple-
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mental or competitive interactions among phytoestrogens. In
addition to an ER-mediated signaling network, there may be
additional ER-independent mechanisms linked to a neuropro-
tective outcome (33, 49–51). A greater effect produced by a
select combination could be the result of concurrent activation
and interaction of these complex signaling cascades. Although
the combination of G plus D plus E exhibited an efficacy com-
parable to or even greater than 17-E2 in neural tissues, the
combination did not induce a significant effect on the uterus,
which may largely be attributable to its high binding selectivity
for ER over ER. In comparison, 17-E2, which shows no
binding preference to either ERs, induced a 2-fold increase in
uterine weight under the same treatment paradigm. Of particular
interest, the combination of G plus D plus E exerted an approx-
imate 10% reduction in uterine weight relative to vehicle-treated
control rats. Despite the absence of a significant difference be-
tween the two groups, it can be speculated that such a slight
down-regulation of uterine weight may become apparent from a
long-term use, leading to a preventive impact against reproduc-
tive cancers.
Clinically, a phytoestrogen combination composed of ratio-
nally defined content (e.g. the combination of G plus D plus E)
has the potential to address the compositional complexity and
potential antagonistic interactions that occur in soy extracts.
Soy-derived extract preparations have been the most common
form used in phytoestrogen intervention studies. However, vari-
ations in the constitutive composition could be significant among
soy extracts obtained from different sources of soy plants and
manufactured using different protocols (17, 52). Possible antag-
onistic interactions could come from many sources (17). In ad-
dition to those derived from intrinsic antiestrogens and between
ER and ER-selective components, some newly formed sub-
stances generated from the extraction process could also pose
undesirable effects counteracting the favorable health-giving
properties of other substances. The antagonistic impact could
conceivably diminish the overall effect and present an undetect-
able or undesirable clinical outcome. As demonstrated in the
present study, the addition of I to the combination of G plus D
plus E not only weakened the ER-binding affinity and selec-
tivity, it negatively impacted the overall activity of G plus D plus
E plus I compared with G plus D plus E. These analyses underlie
a critical notion that the compositional complexity of a random
mixture makes its safety and efficacy unpredictable. In point of
fact, a rationally designed formulation with a clear composition
could maximize the therapeutic potential of individual compo-
nents and lead to a clinically meaningful effect. Another potential
clinical advantage relates to E. Unlike G and D, E is not of plant
origin, yet can be exclusively produced through the metabolism
of D catalyzed by intestinal microbial flora after the intake of soy
products (53). In comparison with D, E has been demonstrated
as a much stronger ER binder and more potent transcriptional
inducer (54). Interestingly, wide variations in the ability to pro-
duce E from D metabolism exist across human populations, with
20–35% of Western adults (55, 56) and 55–60% of Asian pop-
ulations being E producers (57, 58). Therefore, it can be specu-
lated that the E-producing phenotype could serve as a critical
modulator of human response to phytoestrogen treatment. An
enhanced response could occur in E producers compared with
nonproducers. To date, a number of clinical studies have con-
firmed this speculation (59–61). This may also hold true for the
strong link between the many health benefits associated with
phytoestrogen intake and the high prevalence of E-producing
phenotype in Asians. The failure to factor the interindividual
variations of E-producing phenotype could be another major
cause of the disparity in clinical outcomes across studies. Inclu-
sion of E in the combination of G plus D plus E presents the
opportunity to minimize these variations, and make E accessible
in both E producers and nonproducers.
In conclusion, the present study provides evidence in support
of the hypothesis that the ER/ binding profile and neural ac-
tivities derived from individual phytoestrogens could be modi-
fied when they are used in combination. Specifically, the com-
bination of G plus D plus E, which enhanced ER-binding
selectivity and in vitro to in vivo neural responses without elic-
iting a significant impact on uterine growth, has the potential of
a relatively safe alternative approach to conventional HT for
reducing the increased risk of cognitive decline and neurodegen-
erative disease associated with menopause in women.
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